Key takeaways
- 5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that becomes overactive in fat tissue during obesity.
- By slowing NNMT, the compound is designed to preserve nicotinamide and NAD+ and to lift the brake NNMT places on energy metabolism in fat cells.
- In obese mice, NNMT inhibitors of this class reduced fat mass and body weight without changing how much the animals ate, pointing to a shift in energy use rather than appetite.
- The target itself is well validated: genetic knockdown of NNMT also protects mice against diet-induced obesity, which is what first put NNMT on the map as a metabolic switch.
- The evidence is still preclinical. The work is in cells and animals, human trials have not yet been run, and any use should be discussed with a qualified physician.
What is 5-Amino-1MQ?
5-Amino-1MQ is a small molecule built around a 1-methylquinolinium scaffold. It belongs to a class of compounds that inhibit nicotinamide N-methyltransferase, usually shortened to NNMT. Unlike a peptide, it is a compact, membrane-permeable molecule designed to get inside cells and act on an enzyme directly.
NNMT sits at a busy junction of cellular metabolism. It takes nicotinamide, a form of vitamin B3 and a building block the body uses to make NAD+, and tags it with a methyl group to form 1-methylnicotinamide. That single reaction pulls on two important threads at once: the supply of NAD+, the coenzyme that powers energy production, and the pool of methyl groups that cells use for a wide range of regulatory jobs. When NNMT runs too hot, both threads get tugged in the wrong direction.
Interest in 5-Amino-1MQ comes from the observation that NNMT is markedly elevated in the fat tissue of obese and insulin-resistant animals and people. That made it an attractive target to switch off, and 5-Amino-1MQ is one of the most studied tools for doing it.
How it works
The logic behind inhibiting NNMT is to relieve a metabolic brake on fat cells. When NNMT is overactive, it consumes nicotinamide and methyl groups at a high rate. A 2014 study in Nature showed that this matters: knocking down NNMT in fat and liver tissue protected mice against diet-induced obesity, increased their energy expenditure, and improved insulin sensitivity. The researchers traced the effect to NAD+ and methyl-group metabolism, which together set the pace of fuel burning inside the cell.
5-Amino-1MQ aims to reproduce that benefit pharmacologically. By blocking the enzyme rather than deleting the gene, the compound is meant to preserve nicotinamide for NAD+ production and free up methyl groups, which together appear to raise the rate at which fat cells burn energy. Reviews of the field describe NNMT as a regulator of NAD+ and one-carbon metabolism in adipose tissue, which is why inhibiting it is being explored for obesity, type 2 diabetes, and broader metabolic syndrome.
What the research shows
The defining preclinical result came in a 2018 study in Biochemical Pharmacology. Working in diet-induced obese mice, the team showed that selective, membrane-permeable NNMT inhibitors reversed high-fat-diet-induced obesity. Treated animals lost fat mass and body weight, and the effect was reported without a reduction in food intake, which points toward a change in how energy is spent rather than how much is eaten. This is the work most often cited when 5-Amino-1MQ is discussed as a fat-loss compound.
More recent animal work has extended the picture. A 2024 study in Diabetes, Obesity and Metabolism reported that NNMT inhibition mitigated obesity-related metabolic dysfunction, adding to the case that turning the enzyme down improves the metabolic profile, not just the number on the scale. Alongside the small-molecule data, the genetic knockdown findings give the target two independent lines of support: switch NNMT off by deleting the gene, or block it with a drug, and the metabolic direction of travel is the same.
Two 2024 reviews place this in context. One in Frontiers in Pharmacology frames NNMT as a novel therapeutic target for metabolic syndrome, summarizing the adipose-tissue biology and the inhibitor programs aimed at it. A second, in Archives of Pharmacal Research, maps NNMT across its metabolic pathways and the therapeutic strategies being pursued. Both make clear that the science is active and the rationale is strong, while the human chapter has yet to be written.
The potential benefit
The appeal of 5-Amino-1MQ is that it targets metabolism at the source. Rather than suppressing appetite, the mechanism studied in animals shifts fat cells toward burning more energy, which is why the compound is discussed in the same breath as fat loss and metabolic health. Its connection to NAD+ adds a second point of interest, since NAD+ decline is a recurring theme in metabolic and age-related research.
It is worth being clear about where the evidence stands. The encouraging results are in cells and animals, and the consistency between genetic and pharmacological approaches is a genuine strength. Human trials are the next step, and they are what will determine whether the metabolic shift seen in mice translates to people. Anyone considering 5-Amino-1MQ should weigh that early stage and make the decision with a qualified physician after a full assessment.
The evidence
Selected references, each verified against primary sources (PubMed). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. 5-Amino-1MQ is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.